2024-2031年急性腎損傷治療市場（依產品、損傷、通路及地區）

急性腎損傷治療市場評估 - 2024-2031

隨著腎臟相關疾病的盛行率和認知度不斷提高，急性腎損傷 (AKI) 治療市場正在不斷擴大。透析、藥物治療和支持性照護是其中最重要的治療方法。技術發展和診斷方法的改進都促進了市場的發展。預計到 2024 年，市場規模將超過 15.1 億美元，到 2031 年將達到 25.6 億美元。

糖尿病和高血壓等慢性疾病的增加推動了急性腎損傷 (AKI) 治療市場的發展。然而，發展中國家治療成本的上漲和認知度的低落是阻礙因素。政府的措施、醫療基礎設施的改善以及對創新療法的持續探索，對市場成長至關重要。急性腎損傷治療需求的不斷成長預計將推動市場在2024年至2031年間以6.85%的複合年成長率成長。

急性腎損傷治療市場定義/概述

急性腎損傷 (AKI) 的治療包括解決根本病因、維持體液平衡和支持腎功能。這包括藥物治療、必要時進行透析以及監測電解質和廢物水平，以預防併發症並促進康復。

急性腎損傷 (AKI) 的治療重點在於解決根本病因、恢復腎功能並避免併發症。常見的治療方法包括補液、電解質平衡、藥物治療和透析。早期診斷和治療對於避免永久性腎損傷和改善患者預後至關重要。

早期發現、個人化治療方法和再生醫學的進步將重塑急性腎損傷 (AKI) 的治療。基於生物標記的診斷和幹細胞療法等創新預計將透過減緩慢性腎臟病的進展和改善整體腎功能來改善患者的預後。

慢性病的增加是否會推動急性腎損傷治療市場的成長？

糖尿病和高血壓等慢性疾病盛行率的上升是推動急性腎損傷 (美國) 治療市場發展的主要因素。根據美國疾病管制與預防中心 (CDC) 的數據，美國約有 3,700 萬人患有慢性腎臟病(CKD)，而這些疾病通常在早期階段未被發現。

根據美國腎臟病和腎臟病研究所 (NIDDK) 的數據，5-7% 的住院患者會發生急性腎損傷 (AKI)，高達 20% 的重症患者會發展為急性腎損傷 (AKI)。美國腎臟病學與腎臟病學研究所 (USRDS) 2020 年度數據報告指出，醫療保險受益人群中慢性腎臟病 (CKD) 的盛行率正在上升，美國國家腎臟基金會 (National Kidney Foundation) 也強調了糖尿病和高血壓對慢性腎臟病 (CKD) 患者的重大影響。此外，AKI 的盛行率正在急劇上升，凸顯了對更優治療方法的迫切需求。

高昂的治療費用是否會阻礙急性腎損傷治療市場的發展？

急性腎損傷 (AKI) 治療的高昂費用可能會限制市場擴張。根據美國國家醫學圖書館發表的一項研究，AKI 患者的平均住院費用為 24,896 美元，而非 AKI 患者的平均住院費用為 13,425 美元。 AKI 額外增加的 11,471 美元費用可能會給個人和醫療保健系統帶來沉重的經濟負擔。

此外，現代診斷和治療方法的高昂成本可能會阻礙人們獲得及時有效的治療。這種經濟限制因素可能會阻礙市場成長，尤其是在醫療資源匱乏、保險覆蓋率較低的地區。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概況
• 市場亮點

第3章 市場概況

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機遇
• 波特五力分析

第4章急性腎損傷治療市場（依治療類型）

• 藥物治療
• 腎臟替代療法（RRT）

第5章急性腎損傷治療市場（按原因）

• 腎前性AKI
• 原發性急性腎損傷
• 腎後性急性腎損傷

第6章急性腎損傷治療市場（依最終使用者）

• 醫院和診所
• 門診手術中心
• 透析中心

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機遇
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市佔率分析

第10章：公司簡介

• Baxter International Inc
• Fresenius Medical Care AG & Co KGaA
• B. Braun Melsungen AG
• Angion Biomedica Corp
• AM-Pharma
• Quark Pharmaceuticals Inc
• Asahi Kasei Medical Co Ltd
• LG Chem

第11章 市場展望與機遇

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Acute Kidney Injury Treatment Market Valuation - 2024-2031

The Acute Kidney Injury (AKI) therapy market is expanding due to rising prevalence of kidney-related illnesses and increasing awareness. Dialysis, medicine and supportive care are among the most important treatments. Technological developments and enhanced diagnostic methods both contribute to market growth. This is likely to enable the market size surpass USD 1.51 Billion valued in 2024 to reach a valuation of around USD 2.56 Billion by 2031.

Rising chronic disorders such as diabetes and hypertension are propelling the AKI therapy market. However, high treatment costs and low awareness in developing countries provide obstacles. Government initiatives and improvements to healthcare infrastructure are critical for market growth, as is continued research into breakthrough therapeutics. The rising demand for acute kidney injury treatment is enabling the market grow at a CAGR of 6.85% from 2024 to 2031.

Acute Kidney Injury Treatment Market: Definition/ Overview

Acute Kidney Injury (AKI) treatment consists of addressing the underlying cause, maintaining fluid balance and supporting kidney function. This involves drugs, dialysis if necessary and monitoring electrolyte and waste levels to avoid problems and enhance recovery.

Acute kidney injury (AKI) treatment focuses on addressing the underlying cause, restoring kidney function and avoiding complications. Common interventions include hydration control, electrolyte balance, medicine and dialysis. Early diagnosis and treatment are critical for avoiding permanent kidney damage and improving patient outcomes.

Advances in early detection, customized therapeutics and regenerative medicine will shape the treatment of Acute Kidney Injury (AKI). Innovations such as biomarker-based diagnostics and stem cell therapies are projected to enhance patient outcomes by slowing the progression of chronic kidney disease and improving overall kidney function.

Will Rising Prevalence of Chronic Diseases Boost the Growth of Acute Kidney Injury Treatment Market?

The rising incidence of chronic disorders including diabetes and hypertension is a major driver driving the acute kidney injury (AKI) therapy market. According to the Centers for Disease Control and Prevention (CDC), around 37 million US individuals have chronic kidney disease (CKD), which is frequently undetected in the early stages.

According to the NIDDK, AKI affects 5-7% of hospitalized patients and up to 20% of critically ill patients acquire AKI. The USRDS 2020 Annual Data Report cites a rise in CKD prevalence among Medicare beneficiaries, while the National Kidney Foundation emphasizes the significant impact of diabetes and hypertension on CKD patients. Furthermore, the prevalence of AKI has increasing dramatically, highlighting the urgent need for better treatments.

Will High Cost of Treatment Hamper the Acute Kidney Injury Treatment Market?

The high cost of treatment for acute kidney injury (AKI) may limit market expansion. A study published in the National Library of Medicine found that the average hospitalization cost for AKI patients is $24,896, compared to $13,425 for individuals without AKI. This $11,471 additional cost associated with AKI may be a considerable financial burden for people and healthcare systems.

Furthermore, the high costs associated with modern diagnostic and therapeutic approaches may impede access to timely and effective care. This economic constraint may hinder market growth, especially in areas with inadequate healthcare resources or insufficient insurance coverage.

Category-Wise Acumens

Will Decreasing Blood Flow to the Kidneys Drive the Injury Segment?

A decrease in blood supply to the kidneys will cause the acute kidney injury (AKI) phase. Reduced renal perfusion is the major cause of AKI, which is frequently caused by severe dehydration, shock, or heart failure. When blood flow is reduced, the kidneys cannot filter waste adequately, resulting in kidney injury. This pathophysiological mechanism contributes significantly to AKI cases, emphasizing the need of targeting decreased renal perfusion in therapeutic efforts.

The growing awareness and emphasis on controlling and avoiding diseases that cause reduced blood flow to the kidneys is expected to fuel growth in the AKI therapy segment. Early detection and intervention are critical for reducing harm and improving patient outcomes, which encourages the development of focused medicines and diagnostic technologies in this area.

Will Increasing Demand for Managing Kidney Failure by Removing Waste Drive the Dialysis Segment?

The dialysis segment will be driven by an increase in demand for waste removal to manage renal failure. As kidney function deteriorates, dialysis becomes necessary to accomplish the crucial job of removing waste and excess fluid from the blood.

The rise in chronic renal disease, diabetes and hypertension, all of which contribute to kidney failure, emphasizes the importance of effective dialysis solutions. Advances in dialysis technology, as well as increasing awareness of its benefits, help to fuel this trend. With an increasing patient population requiring dialysis, driven by the increasing prevalence of kidney failure, demand for dialysis treatments is likely to rise further, propelling innovation and market expansion in this sector.

Country/Region-wise Acumens

Will High Prevalence of Chronic Diseases Drive the Market in North America?

The rising prevalence of chronic diseases will propel the AKI therapy market in North America. Chronic illnesses common in the region, such as diabetes and hypertension, are important risk factors for acute kidney injury. With millions of people impacted by these disorders, there is an increasing demand for better AKI treatments.

North America's modern healthcare system and high level of care encourage the use of novel medicines and technologies to manage and treat AKI. Furthermore, large investments in R&D, together with increasing awareness of kidney health, contribute to market growth. As chronic disease rates rise, the demand for AKI therapies will stay high, fueling market growth in North America.

Will Increasing Awareness of Kidney Diseases Drive the Market in Asia Pacific Region?

The acute kidney injury (AKI) treatment market in Asia-Pacific will grow due to increasing awareness of kidney illnesses. Growing public and healthcare professional awareness of the prevalence, risk factors and implications of kidney disease is resulting in earlier diagnosis and more proactive treatment. This increasing awareness fuels demand for new diagnostic tools and treatment choices.

Furthermore, educational initiatives and government health programs aiming at improving kidney health help to drive market growth. As the public gets more educated about kidney disease prevention and management, there will be a greater uptake of AKI treatments, driving market growth. Improved awareness contributes to the overall development of healthcare infrastructure and encourages investment in medical technologies, increasing regional market growth.

Competitive Landscape

The acute kidney injury treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the acute kidney injury treatment market include:

Baxter International, Inc.

Fresenius Medical Care AG & Co KGaA

Braun Melsungen AG

Angion Biomedica Corp

AM-Pharma

Quark Pharmaceuticals, Inc.

Asahi Kasei Medical Co Ltd

LG Chem

Acute Kidney Injury Treatment Market Latest Developments

In March 2021, B. Braun Avitum AG, a major manufacturer of medical equipment and pharmaceutical products and services and CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat fatal inflammation, announced the partnership launched a global co-marketing agreement to promote the usage of CytoSorb.

In March 2021, Critical Path Institute (C-Path), a nonprofit organization, announced the commencement of the Acute Kidney Injury (AKI) Project in partnership with the US Food and Drug Administration. The business proposes creating prognostic tools to better anticipate and identify drug-induced kidney damage (DIKI).

In November 2020, Vifor Pharma, a Swiss medicine maker, agreed to pay Angion Biomedica up to USD 80.0 Million for rights to experimental kidney drug ANG-3777

Acute Kidney Injury Treatment Market, By Category

• Product:
• Dialysis
• Intermittent Hemodialysis
• Continuous Renal Replacement Therapy (CRRT)
• Sustained Low-Efficiency Dialysis (SLED)
• Drug Therapy
• Antibiotics
• Diuretics
• Immunosuppressive Agents
• Injury:
• Pre-renal Injury
• Intrinsic Renal Injury
• Post-renal Injury
• Distribution Channel:
• Hospitals
• Ambulatory Surgical Centers
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Acute Kidney Injury Treatment Market, By Treatment Type

• Pharmacological Treatment
• Renal Replacement Therapies (RRT)

5. Acute Kidney Injury Treatment Market, By Cause

• Pre-renal AKI
• Intrinsic AKI
• Post-renal AKI

6. Acute Kidney Injury Treatment Market, By End-User

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Dialysis Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Baxter International Inc
• Fresenius Medical Care AG & Co KGaA
• B. Braun Melsungen AG
• Angion Biomedica Corp
• AM-Pharma
• Quark Pharmaceuticals Inc
• Asahi Kasei Medical Co Ltd
• LG Chem

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References